PepKon
Private Company
Funding information not available
Overview
PepKon is a preclinical-stage biotech leveraging a proprietary peptide platform to develop agonists targeting the TSP-1/CD47 pathway for cancer treatment. Its lead program, PKT16, has shown promising in vitro and preclinical efficacy in refractory chronic lymphocytic leukemia (CLL) and select solid tumors, with plans to enter first-in-human trials around 2025. The company is built on over a decade of academic research, is led by a team with pharmaceutical development expertise, and is funded through private and public sources. PepKon's approach aims to overcome limitations of current therapies by selectively inducing immunogenic cell death in cancer cells while sparing healthy tissues.
Technology Platform
Proprietary platform for designing and optimizing therapeutic peptides that mimic the C-terminal domain of thrombospondin-1 (TSP-1). These peptides act as agonists of the CD47 receptor, triggering a unique form of immunogenic cell death in cancer cells.
Opportunities
Risk Factors
Competitive Landscape
PepKon competes in the crowded CD47-targeting space, which is dominated by large biopharma companies developing blocking antibodies (e.g., magrolimab from Gilead) and SIRPα-Fc fusion proteins. Its key differentiation is its peptide-based agonist mechanism, which aims to directly kill cancer cells via immunogenic cell death rather than blocking the 'don't eat me' signal to enhance phagocytosis. This positions it as a mechanistically distinct player.